Meiji Holdings Co., Ltd. (MEJHY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Meiji Holdings Co., Ltd. (MEJHY) with AI Score 52/100 (Hold). Meiji Holdings Co. , Ltd. operates in the consumer defensive sector, manufacturing and selling a diverse range of food and pharmaceutical products. Market cap: 0, Sector: Consumer defensive.
Last analyzed: Mar 16, 2026Meiji Holdings Co., Ltd. (MEJHY) Consumer Business Overview
Meiji Holdings Co., Ltd. is a diversified consumer defensive company based in Japan, producing dairy, confectionery, nutritional, and pharmaceutical products. With a market capitalization of $6.53 billion and a P/E ratio of 23.50, Meiji operates globally, balancing its food and pharmaceutical segments within the packaged foods industry.
Investment Thesis
Meiji Holdings presents a stable investment profile within the consumer defensive sector, supported by its diversified product range and established market presence. With a market capitalization of $6.53 billion and a dividend yield of 2.57%, the company offers consistent returns. A profit margin of 4.0% and gross margin of 30.2% indicate solid profitability. Growth catalysts include expanding its international footprint and developing innovative products in both the food and pharmaceutical segments. Potential risks involve currency fluctuations and regulatory changes in the pharmaceutical industry. The company's low beta of 0.10 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $6.53 billion, reflecting a substantial market presence.
- P/E ratio of 23.50, indicating a moderate valuation relative to earnings.
- Dividend yield of 2.57%, providing a steady income stream for investors.
- Gross margin of 30.2%, showcasing efficient cost management in production.
- Low beta of 0.10, suggesting lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Diversified product portfolio across food and pharmaceutical segments.
- Strong brand recognition and reputation in Japan.
- Established distribution network.
- Consistent dividend payout.
Weaknesses
- Geographic concentration in Japan and Asia.
- Lower profit margins compared to some competitors.
- Dependence on raw material prices.
- Exposure to regulatory changes in the pharmaceutical industry.
Catalysts
- Ongoing: Expansion of product lines in the functional foods and health supplements category, targeting health-conscious consumers.
- Ongoing: Strategic partnerships with local distributors in emerging markets to increase market penetration.
- Upcoming: Launch of new pharmaceutical products targeting infectious diseases in Q4 2026.
- Ongoing: Investment in e-commerce infrastructure to enhance online sales and customer engagement.
- Ongoing: Focus on sustainability initiatives to improve brand image and attract environmentally conscious consumers.
Risks
- Potential: Currency fluctuations between the Japanese Yen and the U.S. Dollar could impact ADR value.
- Ongoing: Intense competition in the food and pharmaceutical industries may pressure profit margins.
- Potential: Regulatory changes in the pharmaceutical industry could affect product approvals and pricing.
- Potential: Economic downturns could reduce consumer spending on discretionary food items.
- Ongoing: Supply chain disruptions could impact production and distribution.
Growth Opportunities
- Expanding into emerging markets presents a significant growth opportunity for Meiji. The increasing disposable incomes and changing dietary habits in regions like Southeast Asia and Africa create demand for packaged foods and nutritional products. By tailoring its product offerings to local tastes and preferences, Meiji can capture a larger market share. This expansion could contribute to a 10-15% increase in revenue over the next five years.
- Innovation in functional foods and health supplements aligns with growing consumer interest in health and wellness. Meiji can leverage its expertise in dairy and nutritional products to develop new offerings that cater to specific health needs, such as probiotics, protein-enriched foods, and immunity-boosting supplements. The global functional foods market is projected to reach $278 billion by 2028, offering substantial growth potential.
- Developing new pharmaceutical products, particularly in the areas of infectious diseases and central nervous system disorders, can drive revenue growth. Meiji's research and development capabilities, combined with strategic partnerships, can lead to the discovery and commercialization of innovative drugs. The global pharmaceutical market is expected to reach $1.57 trillion by 2028, providing a large addressable market.
- Strengthening its e-commerce presence will allow Meiji to reach a wider customer base and capitalize on the growing trend of online shopping. By investing in its online platform and digital marketing efforts, Meiji can enhance its brand visibility and drive sales. E-commerce sales of packaged foods and pharmaceuticals are projected to grow by 12-15% annually over the next five years.
- Strategic acquisitions and partnerships can expand Meiji's product portfolio and geographic reach. By acquiring companies with complementary products or technologies, Meiji can diversify its revenue streams and enter new markets. This strategy can accelerate growth and enhance the company's competitive position. The M&A activity in the food and pharmaceutical industries is expected to remain robust, providing opportunities for strategic deals.
Opportunities
- Expansion into emerging markets.
- Development of new functional foods and health supplements.
- Innovation in pharmaceutical products.
- Strengthening e-commerce presence.
Threats
- Intense competition in the food and pharmaceutical industries.
- Currency fluctuations.
- Changing consumer preferences.
- Economic downturns.
Competitive Advantages
- Strong brand recognition and reputation in Japan and other Asian markets.
- Diversified product portfolio across food and pharmaceutical segments.
- Established distribution network and supply chain.
- Research and development capabilities in both food and pharmaceutical areas.
About MEJHY
Founded in 1916 and headquartered in Tokyo, Japan, Meiji Holdings Co., Ltd. has evolved into a multinational corporation operating through its Food and Pharmaceutical segments. The Food segment offers a wide array of products, including yogurt, cheese, milk, beverages, butter, margarine, cream, ice cream, ready meals, chocolates, gummy products, chewing gums, sports nutrition products, infant formula, liquid diets, and beauty supplements. The Pharmaceutical segment provides OTC medicines, feedstuffs, corn sweeteners, and sugar, alongside transportation and distribution services. In pharmaceuticals, Meiji develops drugs for infectious diseases and central nervous system disorders, as well as generic drugs, agricultural and livestock chemicals, human and animal vaccines, blood plasma products, and veterinary drugs for livestock and fisheries. The company also provides products for companion animals, including anesthetics, painkillers, and dietary supplements. Meiji's diversified portfolio and global reach position it as a key player in both the food and pharmaceutical industries.
What They Do
- Manufactures and sells dairy products such as yogurt, cheese, and milk.
- Produces confectioneries including chocolates, gummy products, and chewing gums.
- Offers nutritional products like sports nutrition items, infant formula, and liquid diets.
- Develops and markets pharmaceutical products for infectious diseases and central nervous system disorders.
- Provides OTC medicines, feedstuffs, corn sweeteners, and sugar.
- Offers veterinary drugs for livestock, fisheries, and companion animals.
Business Model
- Meiji generates revenue through the sale of food products, including dairy, confectionery, and nutritional items.
- The company earns revenue from the sale of pharmaceutical products, including prescription drugs and OTC medicines.
- Meiji's business model includes a focus on research and development to create innovative products.
- The company utilizes a distribution network to reach consumers in Japan and internationally.
Industry Context
Meiji Holdings operates within the consumer defensive sector, specifically in the packaged foods and pharmaceuticals industries. The packaged foods market is characterized by stable demand and consistent growth, driven by changing consumer preferences and health trends. The pharmaceutical industry is subject to stringent regulations and high R&D costs. Meiji competes with companies like CFEIY (Campbell Soup), CHFLF (Chocolate Factory), EMLZF (Emmi AG), GLAPY (Glanbia), and GPAGF (Grupo Bimbo), all vying for market share through product innovation and brand recognition. The company's diversified portfolio allows it to navigate the competitive landscape effectively.
Key Customers
- Individual consumers who purchase Meiji's food and confectionery products.
- Healthcare providers and patients who use Meiji's pharmaceutical products.
- Livestock and fishery farmers who use Meiji's veterinary drugs.
- Retailers and distributors who sell Meiji's products to end consumers.
Financials
Chart & Info
Meiji Holdings Co., Ltd. (MEJHY) stock price: Price data unavailable
Latest News
No recent news available for MEJHY.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MEJHY.
Price Targets
Wall Street price target analysis for MEJHY.
MoonshotScore
What does this score mean?
The MoonshotScore rates MEJHY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Katsunari Matsuda
CEO
Katsunari Matsuda serves as the CEO of Meiji Holdings Co., Ltd., leading a workforce of 17,270 employees. His career spans several decades in the food and pharmaceutical industries. Prior to his current role, he held various leadership positions within Meiji, overseeing strategic planning, product development, and international expansion. Matsuda's expertise lies in driving innovation and operational efficiency to enhance the company's competitiveness.
Track Record: Under Katsunari Matsuda's leadership, Meiji Holdings has focused on expanding its global footprint and strengthening its product portfolio. He has overseen the launch of several successful new products and has implemented initiatives to improve supply chain management and reduce costs. Matsuda has also emphasized sustainability and corporate social responsibility, aligning the company's operations with environmental and social goals.
Meiji Holdings Co., Ltd. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. MEJHY is an ADR for Meiji Holdings Co., Ltd., allowing U.S. investors to invest in the company without directly dealing with foreign markets. Each MEJHY ADR represents a specific number of Meiji Holdings' shares traded on the Tokyo Stock Exchange.
- Home Market Ticker: Tokyo Stock Exchange, Japan
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: MEJH
MEJHY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market, indicating that Meiji Holdings Co., Ltd. has limited reporting requirements and may not meet the listing standards of major exchanges like the NYSE or NASDAQ. Companies on this tier often have lower trading volumes and less regulatory oversight compared to those listed on higher tiers or major exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to low trading volumes.
- Less stringent reporting requirements and regulatory oversight.
- Potential for wider bid-ask spreads and price volatility.
- Information asymmetry due to limited public information.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive position.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC securities.
- Monitor trading volumes and price movements.
- Consult with a financial advisor.
- Established history and operations in Japan.
- Presence in the consumer defensive sector.
- Availability of some financial information, even if limited.
- ADR structure allowing U.S. investors to access the stock.
- CEO with a documented background.
Meiji Holdings Co., Ltd. Stock: Key Questions Answered
What does Meiji Holdings Co., Ltd. do?
Meiji Holdings Co., Ltd. is a diversified company that operates in both the food and pharmaceutical industries. In the food sector, it manufactures and sells a wide range of products, including dairy items, confectioneries, and nutritional supplements. Its pharmaceutical division focuses on developing and marketing drugs for infectious diseases, central nervous system disorders, and veterinary medicine. The company aims to provide high-quality products that enhance the health and well-being of consumers globally.
What do analysts say about MEJHY stock?
Analyst coverage of MEJHY is limited due to its OTC listing and ADR Level I status. However, the company's stable presence in the consumer defensive sector and consistent dividend payouts are generally viewed positively. Key valuation metrics, such as the P/E ratio of 23.50, suggest a moderate valuation compared to its peers. Growth considerations include the company's expansion into emerging markets and its focus on innovative products in both the food and pharmaceutical segments. Investors should conduct their own due diligence and consider the risks associated with OTC trading.
What are the main risks for MEJHY?
The main risks for Meiji Holdings Co., Ltd. include currency fluctuations, intense competition, regulatory changes, economic downturns, and supply chain disruptions. As an ADR, MEJHY is subject to currency risk, as its value is affected by changes in the exchange rate between the Japanese Yen and the U.S. Dollar. The food and pharmaceutical industries are highly competitive, which can pressure profit margins. Regulatory changes in the pharmaceutical sector can impact product approvals and pricing. Economic downturns can reduce consumer spending on discretionary food items. Supply chain disruptions can impact production and distribution.
What are the key factors to evaluate for MEJHY?
Meiji Holdings Co., Ltd. (MEJHY) currently holds an AI score of 52/100, indicating moderate score. Key strength: Diversified product portfolio across food and pharmaceutical segments.. Primary risk to monitor: Potential: Currency fluctuations between the Japanese Yen and the U.S. Dollar could impact ADR value.. This is not financial advice.
How frequently does MEJHY data refresh on this page?
MEJHY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MEJHY's recent stock price performance?
Recent price movement in Meiji Holdings Co., Ltd. (MEJHY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio across food and pharmaceutical segments.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MEJHY overvalued or undervalued right now?
Determining whether Meiji Holdings Co., Ltd. (MEJHY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MEJHY?
Before investing in Meiji Holdings Co., Ltd. (MEJHY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may have limited accuracy and availability.
- AI analysis is pending and may provide additional insights.